Email Alert RSS
Volume 11 Issue 2
Mar.  2020
Turn off MathJax
Article Contents
Abstract
References
Related Articles
Cheng-mei HE, Feng-chun ZHANG. Belimumab:A New Targeted Drug for Systemic Lupus Erythematosus[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(2): 130-134. DOI: 10.3969/j.issn.1674-9081.20190114
Citation: Cheng-mei HE, Feng-chun ZHANG. Belimumab:A New Targeted Drug for Systemic Lupus Erythematosus[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(2): 130-134. DOI: 10.3969/j.issn.1674-9081.20190114
shu

Belimumab:A New Targeted Drug for Systemic Lupus Erythematosus

  • Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

More Information
  • Corresponding author:

    ZHANG Feng-chun Tel: 86-10-69155007, E-mail: zhangfccra@aliyun.com

  • Received Date: June 18, 2019
  • Issue Publish Date: March 29, 2020
    Graphical Abstract
    • Abstract
  • Systemic lupus erythematosus(SLE) is a complicated autoimmune disease characterized by aberrant B cell activation. Belimumab is a human monoclonal antibody, which can reduce active B cells through binding to the B-cell-activating factor of the tumor necrosis factor family(BAFF). In 2011, the US Food and Drugs Administration approved belimumab as a new drug option for SLE patients. This article mainly discusses the mechanism and relevant clinical trials of belimumab and looks forward to its future.
    • FullText(HTML)
    • References (32)
  • [1]
    Tsokos GC, Lo MS, Costa Reis P, et al. New insights into the immunopathogenesis of systemic lupus erythematosus[J]. Nat Rev Rheumatol, 2016, 12:716-730. DOI: 10.1038/nrrheum.2016.186
    [2]
    Kamal A, Khamashta M. The efficacy of novel B cell biologics as the future of SLE treatment:a review[J]. Autoimmun Rev, 2014, 13:1094-1101. DOI: 10.1016/j.autrev.2014.08.020
    [3]
    Sanz I, Lee FE. B cells as therapeutic targets in SLE[J]. Nat Rev Rheumatol, 2010, 6:326-337. DOI: 10.1038/nrrheum.2010.68
    [4]
    Sanz I. Rationale for B cell targeting in SLE[J]. Semin Immunopathol, 2014, 36:365-375. DOI: 10.1007/s00281-014-0430-z
    [5]
    Schneider P, MacKay F, Steiner V, et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth[J]. J Exp Med, 1999, 189:1747-1756. DOI: 10.1084/jem.189.11.1747
    [6]
    Vincent FB, Saulep-Easton D, Figgett WA, et al. The BAFF/APRIL system:emerging functions beyond B cell biology and autoimmunity[J]. Cytokine Growth Factor Rev, 2013, 24:203-215. DOI: 10.1016/j.cytogfr.2013.04.003
    [7]
    Vincent FB, Morand EF, Schneider P, et al. The BAFF/APRIL system in SLE pathogenesis[J]. Nat Rev Rheumatol, 2014, 10:365-373. DOI: 10.1038/nrrheum.2014.33
    [8]
    Patke A, Mecklenbrauker I, Erdjument-Bromage H, et al. BAFF controls B cell metabolic fitness through a PKC beta- and Akt-dependent mechanism[J]. J Exp Med, 2006, 203:2551-2562. DOI: 10.1084/jem.20060990
    [9]
    Kayagaki N, Yan M, Seshasayee D, et al. BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2[J]. Immunity, 2002, 17:515-524. DOI: 10.1016/S1074-7613(02)00425-9
    [10]
    Gross JA, Dillon SR, Mudri S, et al. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease:impaired B cell maturation in mice lacking BLyS[J]. Immunity, 2001, 15:289-302. DOI: 10.1016/S1074-7613(01)00183-2
    [11]
    Schiemann B, Gommerman JL, Vora K, et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway[J]. Science, 2001, 293:2111-2114. DOI: 10.1126/science.1061964
    [12]
    Saulep-Easton D, Vincent FB, Quah PS, et al. The BAFF receptor TACI controls IL-10 production by regulatory B cells and CLL B cells[J]. Leukemia, 2016, 30:163-172. DOI: 10.1038/leu.2015.174
    [13]
    Ahmed SS, Wang XN, Norden J, et al. Identification and validation of biomarkers associated with acute and chronic graft versus host disease[J]. Bone Marrow Transplant, 2015, 50:1563-1571. DOI: 10.1038/bmt.2015.191
    [14]
    Shlomchik MJ, Madaio MP, Ni D, et al. The role of B cells in lpr/lpr-induced autoimmunity[J]. J Exp Med, 1994, 180:1295-1306. DOI: 10.1084/jem.180.4.1295
    [15]
    Yaniv G, Twig G, Shor DB, et al. A volcanic explosion of autoantibodies in systemic lupus erythematosus:a diversity of 180 different antibodies found in SLE patients[J]. Autoimmun Rev, 2015, 14:75-79. DOI: 10.1016/j.autrev.2014.10.003
    [16]
    Vaughn SE, Kottyan LC, Munroe ME, et al. Genetic susceptibility to lupus:the biological basis of genetic risk found in B cell signaling pathways[J]. J Leukocyte Biol, 2012, 92:577-591. DOI: 10.1189/jlb.0212095
    [17]
    Sun C, Molineros JE, Looger LL, et al. High-density genotyping of immune-related loci identifies new SLE risk variants in individuals with Asian ancestry[J]. Nat Genet, 2016, 48:323-330. DOI: 10.1038/ng.3496
    [18]
    Steri M, Orru V, Idda ML, et al. Overexpression of the Cytokine BAFF and Autoimmunity Risk[J]. New Engl J Med, 2017, 376:1615-1626. DOI: 10.1056/NEJMoa1610528
    [19]
    Pers JO, Daridon C, Devauchelle V, et al. BAFF overexpression is associated with autoantibody production in autoimmune diseases[J]. Ann N Y Acad Sci, 2005, 1050:34-39. DOI: 10.1196/annals.1313.004
    [20]
    Gross JA, Johnston J, Mudri S, et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease[J]. Nature, 2000, 404:995-999. DOI: 10.1038/35010115
    [21]
    Mackay F, Woodcock SA, Lawton P, et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations[J]. J Exp Med, 1999, 190:1697-1710. DOI: 10.1084/jem.190.11.1697
    [22]
    Ding H, Wang L, Wu X, et al. Blockade of B-cell-activating factor suppresses lupus-like syndrome in autoimmune BXSB mice[J]. J Cell Mol Med, 2010, 14:1717-1725. http://europepmc.org/articles/PMC3829033/
    [23]
    Jacob CO, Pricop L, Putterman C, et al. Paucity of clinical disease despite serological autoimmunity and kidney pathology in lupus-prone New Zealand mixed 2328 mice deficient in BAFF[J]. J Immunol, 2006, 177:2671-2680. DOI: 10.4049/jimmunol.177.4.2671
    [24]
    Baker KP, Edwards BM, Main SH, et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator[J]. Arthritis Rheum, 2003, 48:3253-3265. DOI: 10.1002/art.11299
    [25]
    Nakayamada S, Tanaka Y. BAFF- and APRIL-targeted therapy in systemic autoimmune diseases[J]. Inflamm Regen, 2016, 36:6. DOI: 10.1186/s41232-016-0015-4
    [26]
    Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus:a randomised, placebo-controlled, phase 3 trial[J]. Lancet, 2011, 377:721-731. DOI: 10.1016/S0140-6736(10)61354-2
    [27]
    Furie R, Petri M, Zamani O, et al. A phase Ⅲ, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus[J]. Arthritis Rheum, 2011, 63:3918-3930. DOI: 10.1002/art.30613
    [28]
    Dooley MA, Houssiau F, Aranow C, et al. Effect of belimumab treatment on renal outcomes:results from the phase 3 belimumab clinical trials in patients with SLE[J]. Lupus, 2013, 22:63-72. DOI: 10.1177/0961203312465781
    [29]
    Stohl W, Schwarting A, Okada M, et al. Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythema-tosus:A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study[J]. Arthritis Rheumatol, 2017, 69:1016-1027. DOI: 10.1002/art.40049
    [30]
    Zhang F, Bae SC, Bass D, et al. A pivotal phase Ⅲ, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea[J]. Ann Rheum Dis, 2018, 77:355-363. DOI: 10.1136/annrheumdis-2017-211631
    [31]
    Jordan NP, D'Cruz DP. Efficacy, pharmacokinetic and pharmacodynamic profile of belimumab for systemic lupus erythematosus[J]. Expert Opin Drug Metab Toxicol, 2015, 11:1635-1645. DOI: 10.1517/17425255.2015.1077808
    [32]
    Ginzler EM, Wallace DJ, Merrill JT, et al. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus[J]. J Rheumatol, 2014, 41:300-309. DOI: 10.3899/jrheum.121368
    • Related Articles

  • Related Articles

    [1]LAN Sihan, FENG Min. Phylogenetic Analyses of HPV53 and Prediction of B and T Cell Epitopes[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(6): 1364-1371. DOI: 10.12290/xhyxzz.2024-0138
    [2]LIU Yanting, ZHANG Lu, CHEN Miao, ZHANG Yan, WEI Chong, PAN Boju, ZHAO Jiawei. A Case of Small B-cell Lymphocytic Lymphoma Diagnosed One Year after Evans Syndrome[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(3): 423-426. DOI: 10.12290/xhyxzz.20200063
    [3]TAN Yu-ting, SHI Xiao-chun, LIU Xiao-qing. Testing and Prophylaxis of Latent Tuberculosis Infection in Patients Receiving Tumor Necrosis Factor-α Antagonists[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(1): 86-91. DOI: 10.12290/xhyxzz.20180406
    [4]Chao WANG, Yang-yu ZHAO. Standardize Clinical Medication and Improve Maternal and Neonatal Outcomes: Interpretation on Prevention of Group B Streptococcal Early-onset Disease in Newborns: ACOG Committee Opinion, Number 797[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(4): 402-407. DOI: 10.3969/j.issn.1674-9081.2020.04.008
    [5]Ju QIAO, Feng LI, Chun-xia HE, Chao WU, Hong-zhong JIN. Effects of the Receptor-IgG Fc Fusion Protein of Recombinant Type Ⅱ Human Tumor Necrosis Factor-α on the Levels of Serum Adipokines in Psoriatic Patients: A Prospective Non-randomized Controlled Trial[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(3): 243-248. DOI: 10.3969/j.issn.1674-9081.2019.03.010
    [6]Qi GUO, Qi-wen YANG, Jing HU, Jin-song GAO, Jun-tao LIU. Comparison of Two Screening Methods of Virginal Group B Streptococcus Colonization in Late Pregnancy[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(3): 242-245. DOI: 10.3969/j.issn.1674-9081.2018.03.010
    [7]Zheng-zuo SHENG, Yi-qing DU, Hua-qi YIN, Qiang WANG, Cai-peng QIN, Xiao-wei ZHANG, Lu-ping YU, Bo YANG, Shi-jun LIU, Tao XU. Expression of Non-B Lymphocyte Immunoglobulin G in Bladder Cancer and Its Biological Function[J]. Medical Journal of Peking Union Medical College Hospital, 2017, 8(4-5): 258-262. DOI: 10.3969/j.issn.1674-9081.2017.05.012
    [8]Qian CAO. The Crucial Problems in the Treatment of Crohn's Disease with Anti-tumor Necrosis Factor-α Monoclonal Antibody[J]. Medical Journal of Peking Union Medical College Hospital, 2017, 8(4-5): 207-209. DOI: 10.3969/j.issn.1674-9081.2017.05.003
    [9]Ying ZHANG, Jin-song GAO, Jun-tao LIU, Hai-yuan LIU, Ying-na SONG, Xiao-ming GONG, Zhi-jing SUN. Effectiveness of B-lynch Suture in Treatment and Prevention of Postpartum Hemorrhage[J]. Medical Journal of Peking Union Medical College Hospital, 2013, 4(2): 174-177. DOI: 10.3969/j.issn.1674-9081.2013.02.019
    [10]Lin WANG, Wen ZHANG, Meng-tao LI, Yan ZHAO. Correlation of Memory B Cell and B Cell Activation Factor with Clinical Indicators in Primary Sj?gren's Syndrome Patients and Their First-degree Relatives[J]. Medical Journal of Peking Union Medical College Hospital, 2010, 1(2): 132-136.

  • Cited by

    Periodical cited type(8)

    1. 黄悦，洪金辉，杨穗碧，姜心怡，龚宇晴，吴静. 靶向淋巴细胞治疗系统性红斑狼疮的研究进展. 中国免疫学杂志. 2024(10): 2236-2242 .
    2. 朱栋栋. 一线教师视角下高中生物学原创试题命制的过程及实践反思——以“系统性红斑狼疮”一题为例. 教学月刊·中学版(教学参考). 2024(12): 71-74 .
    3. 吴春叶，邢钧，龚宝琪. 贝利尤单抗治疗初发系统性红斑狼疮的短期疗效观察. 天津医药. 2023(07): 771-775 .
    4. 王敏，王明霞，邹婵娟，颜丝语，何善智，丁菱. 贝利尤单抗治疗活动性狼疮性肾炎的临床疗效及不良反应. 中国医学前沿杂志(电子版). 2023(11): 65-70 .
    5. 王娟，汪奎，牛彩琴. 贝利木单抗治疗系统性红斑狼疮的有效性和安全性的系统评价. 医学信息. 2021(21): 65-68 .
    6. 许蕾，朱芸，张昊. 贝利尤单抗治疗系统性红斑狼疮的短期临床观察. 中国医药导报. 2021(31): 96-99 .
    7. 杨先远，王红胜. 单克隆抗体治疗系统性红斑狼疮的临床研究进展. 中国生物制品学杂志. 2021(12): 1511-1515 .
    8. 邓江红，李彩凤. 提高对儿童系统性红斑狼疮的认识. 协和医学杂志. 2020(03): 276-282 . 本站查看

    Other cited types(2)

Catalog

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (617) PDF downloads (576) Cited by(10)
    Related
    Links: National Health Commission of the People's Republic of China Chinese Academy of Medical Sciences(CAMS) AMLC Check CNKI Database CNKI Term Online Chinese General Practice
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return
    x Close Forever Close